| 05th week of 2016 patent applcation highlights part 10 |
| Patent application number | Title | Published |
|---|
| 20160030446 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE - This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2016-02-04 |
| 20160030447 | Antiviral Activity of Novel Bicyclic Heterocycles - The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim | 2016-02-04 |
| 20160030448 | Uses for 4, 17 -dihydroxyandrost-4-ene-3-one - The present invention relates to novel uses of 4,17β-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of breast cancer in mammals irrespective of the estrogen-receptor status of the tumor. | 2016-02-04 |
| 20160030449 | TRANSDERMAL CREAM - This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described. | 2016-02-04 |
| 20160030450 | TOPICAL CORTICOSTEROID COMPOSITIONS - Compositions for the topical administration of an active agent comprise a corticosteroid and a fatty alcohol as a skin penetration enhancer, in the form of topical sprays. Processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders, are described. | 2016-02-04 |
| 20160030451 | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF BACILLUS ANTHRACIS INFECTIONS - Methods and compositions for the treatment of | 2016-02-04 |
| 20160030452 | Minocycline Derivatives - This invention relates generally to minocycline derivatives, and to compositions, including pharmaceutical compositions, containing such minocycline derivatives. The invention also relates to methods of synthesizing minocycline derivatives and to methods for using such minocycline derivatives as anti-bacterial agents for treating or preventing infections. | 2016-02-04 |
| 20160030453 | METHODS OF INCREASING ORAL BIOAVAILABILITY OF TETRACYCLINES - Methods for increasing the oral bioavailability of tetracycline compounds are described. | 2016-02-04 |
| 20160030454 | CANCER THERAPY - The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities. | 2016-02-04 |
| 20160030455 | Drink Product and Use Thereof - A drink product having pharmaceutical compositions as an active ingredients of at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed. This invention relates to certain drink products that generally are aqueous solutions containing Genistein (optionally), at least one phosphorylated myoinositol having 1 to 9 phosphate groups (and/or any of the optical isomers thereof) optionally enriched with any or all of myoinositol, optical isomers of myoinositol, electrolytes, flavors, vitamins, free radical scavengers, and sweeteners. | 2016-02-04 |
| 20160030456 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZ- YL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system. | 2016-02-04 |
| 20160030457 | TUMOR-SELECTIVE COMBINATION THERAPY - The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1. | 2016-02-04 |
| 20160030458 | TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS - Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor. | 2016-02-04 |
| 20160030459 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC CONDITIONS - Compositions and methods are provided herein for treatment of allergic conditions, by administration of an adjuvant composition, with or without allergen. | 2016-02-04 |
| 20160030460 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND - The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1Hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy. | 2016-02-04 |
| 20160030461 | MICRORNAS AND USES THEREOF - The present invention provides novel microRNAs and their uses. | 2016-02-04 |
| 20160030462 | Methods of Manipulating the Fate of Cells - A method of manipulating the fate of a cell, which comprises contacting the cell with at least one of (a) a cell fate-determining untranslated/noncoding RNA species (cuR), (b) a modified cuR, or (c) a compound that modifies or affects cuR, under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. Another aspect of the invention relates to a method of manipulating the fate of a cell by contacting the cell with a compound that affects a fate-determining mechanism involving homologous nucleic acid interactions of RNA:RNA or RNA:DNA or resolution of such interactions under conditions sufficient to cause a cell-changing or cell-maintaining fate that results in cell regeneration, cell differentiation or cell death, so that an increase of desirable cells or a decrease in undesirable cells can be obtained. The invention generates cell fate or cell maintenance in a subject, such as a human, so that an increase of desirable cells or a decrease in undesirable cells can be obtained in the subject. This feature can be applied to a therapeutic method of treating a condition in a subject. | 2016-02-04 |
| 20160030463 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INSULIN RESISTANCE OR ABNORMAL LEVELS OF CIRCULATING LIPIDS IN A MAMMAL - The present invention includes compositions useful for treating or preventing abnormal levels of circulating lipids in a mammal in need thereof, and methods using same. The compositions of the invention normalize levels of circulating lipids in the mammal, and do not cause the toxic side-effects known to occur with currently available lipid-managing medications, such as monotherapies using niacin or fibrates. | 2016-02-04 |
| 20160030464 | IMMUNOMODULATING COMPOUNDS AND RELATED COMPOSITIONS AND METHODS - Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile. | 2016-02-04 |
| 20160030465 | TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS - Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue. | 2016-02-04 |
| 20160030466 | USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR IMPROVING BONE DEVELOPMENT AND FORMATION AND/OR FOR IMPROVING COGNITIVE AND CNS DEVELOPMENT IN OFFSPRING - The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, and a non-absorbent carbohydrate and/or an indigestible carbohydrate. | 2016-02-04 |
| 20160030467 | Modified Pectins, Compositions and Methods Related Thereto - The present invention provides compositions of modified pectin and methods for preparing and using them. | 2016-02-04 |
| 20160030468 | Method, Composition, and Articles For Improving Joint Lubrication - Articles for increasing lubrication of a joint are described herein. The articles include resorbable, biocompatible particles having a glass transition temperature within a joint of less than about 37° C. and capable of increasing fluid movement within the joint compared to synovial fluid, viscosupplemental fluid, or combinations thereof A composition for increasing lubrication of a joint is also disclosed. The composition includes the resorbable, biocompatible particles and a carrier fluid. Methods of lubricating a joint and treating disease affecting the joint such as osteoarthritis are also described herein. The methods include introducing the resorbable, biocompatible particles into a joint. | 2016-02-04 |
| 20160030469 | Human End Uses for a Gas Transporting Rheological Medium - A method of delivering at least one therapeutic gas to a tissue site for treating acne, sunburn, scarring, a thermal burn, wrinkling, age spots, eczema, contact dermatitis, itching and a rash. The method comprises dissolving the gas in a liquid solvent that includes a thickening agent to create a solution, transporting that solution to the tissue site, and then releasing said gas at said tissue site for treating the skin-related ailment. | 2016-02-04 |
| 20160030470 | LIQUIDS RICH IN NOBLE GAS AND METHODS OF THEIR PREPARATION AND USE - Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided. The present invention relates generally to the fields of molecular biology, medicine and nutraceuticals. More particularly, it concerns methods for oral delivery of inert gas compositions, such as Xenon or Argon, for the treatment and prevention of disease. | 2016-02-04 |
| 20160030471 | HYPERSATURATED GAS IN LIQUID - Dispersing a gas in a liquid to provide a mixture of saturated, supersaturated or hypersaturated solution to provide a suspension of bubbles containing gas therein. | 2016-02-04 |
| 20160030472 | XENON-BASED ANESTHETIC GAS COMPOSITION USABLE DURING AN ENDARTERECTOMY INVOLVING THE CLAMPING OF THE CAROTID ARTERY - A xenon-based anesthetic gas to be used, via inhalation, to maintain or preserve cerebral perfusion during an endarterectomy involving the clamping of the carotid artery in a mammal under general anesthesia. The xenon is preferably used in combination with at least one injectable anesthetic morphine agent such as remifentanil, sulfentanil, fentanyl, and alfentanil. Advantageously, the xenon is mixed with an oxygen-containing gas and administered to the patient after the patient has been anesthetized, put to sleep, and intubated. The use of xenon makes it possible to achieve a reduction in the pressure gradient during the clamping of the internal carotid artery relative to the usual anesthetic agents, and to achieve stable hemodynamics. | 2016-02-04 |
| 20160030473 | DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF - The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation. | 2016-02-04 |
| 20160030474 | Brain, Spinal and Nerve Injury Treatment - A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound. | 2016-02-04 |
| 20160030475 | USE OF A CLAY PRODUCT OR A CLAY BLEND PRODUCT TO DECREASE THE EFFECTS OF BACTERIAL DISEASE IN SHRIMP - Applicants have examined two | 2016-02-04 |
| 20160030476 | Compositions, Methods And Devices For Promoting Wound Healing And Reducing Infection - Compositions, methods and devices are provided for promoting healing and preventing and treating infection in mammalian subjects. The compositions include pharmacologically active, protease inhibiting, cytokine protecting, aqueous media soluble sulfonated materials, optionally associated with one or more secondary therapeutic agents or carriers, to reduce one or more of inflammation, bacterial proliferation and proteolytic activity. Additionally provided are solubility increasing, stability increasing, toxicity decreasing thiol compounds associated with an antimicrobial compound and optionally secondary therapeutic agents to reduce one or more of inflammation and bacterial infection. Combinations of sulfonated and thiol compounds provide pharmacologically active, protease inhibiting, cytokine protecting, aqueous media soluble, antibacterial, stable, toxicity decreasing, solubility increasing compounds for treating wounds, including burns, in humans and other mammals. | 2016-02-04 |
| 20160030477 | GENE CORRECTION OF SCID-RELATED GENES IN HEMATOPOIETIC STEM AND PROGENITOR CELLS - The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into the genome of a cell for provision of proteins lacking or deficient in SCID. | 2016-02-04 |
| 20160030478 | MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE | 2016-02-04 |
| 20160030479 | MODIFIED T LYMPHOCYTES - Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer. | 2016-02-04 |
| 20160030480 | Cellular Therapy for Ocular Degeneration - Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45. | 2016-02-04 |
| 20160030481 | IL-18 INHIBITION FOR PROMOTION OF EARLY HEMATOPOIETIC PROGENITOR EXPANSION - Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of IL-18 to a recipient subject and also administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of IL-18 to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described. | 2016-02-04 |
| 20160030482 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS - The invention encompasses compositions and method of treating a vascular disease such as peripheral artery disease, The methods involve—administering to a patient in need thereof, an effective amount of a composition comprising a population of cells such as mesenchymal stem cells (MSCs) and a non-muscle myosin 0 antagonist such as blebbistatin. Non-muscle myosin II antagonists are disclosed to surprisingly and dramatically accelerate MSC-triggered regeneration of damaged tissues arid unexpectedly and drastically reduce severe complications of stem cell treatment. | 2016-02-04 |
| 20160030483 | MATERIALS AND METHODS FOR TREATING ALLERGIC AND INFLAMMATORY CONDITIONS - The subject invention provides for the utilization of bone-marrow derived stem cells in the treatment of allergic and inflammatory diseases. In one embodiment, the invention provides for treatment of asthma. Bone-marrow derived stem cells can be used for decreasing inflammation and alter the course of immune response in the lung. | 2016-02-04 |
| 20160030484 | MAMMALIAN PLURIPOTENT STEM CELLS, METHODS FOR THEIR PRODUCTION, AND USES THEREOF - The disclosure relates to nerve derived adult pluripotent stem cells characterized by expression of Oct4, Sox2, c-Myc, and Klf4, methods for obtaining them, and their use. | 2016-02-04 |
| 20160030485 | ADULT CARDIAC STEM CELL POPULATION - The present invention relates to the identification, isolation, expansion and characterization of a specific type of multipotent adult cardiac stem cell. These adult stem cells are characterised in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. In particular, the cells express SOX17 and GATA4, but do not express Oct4, Nanog, c-kit and telomerase reverse transcriptase. These cells are able to differentiate into one or more of the following cell types: adipocytes, osteocytes, endothelial cells and/or smooth muscle cells. They also display an unprecedented capacity for immunoregulation as well as providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium. | 2016-02-04 |
| 20160030486 | PREPARATION OF COMPOSITIONS TO TREAT AND TREATMENT OF OSTEOARTHRITIS USING ADIPOSE-DERIVED STROMAL VASCULAR FRACTION CELLS - A method for preparing a treatment composition for treatment of osteoarthritis including un-cultured stromal vascular fraction cells from adipose tissue includes direct aspiration of material of a centrifugally-formed pellet phase including stromal vascular fraction cells from enzymatically-digested adipose tissue from an internal containment volume of a portable apparatus through an aspiration tube inserted into the pellet phase and into a fluid receptacle located outside of the internal containment volume. The treatment composition may be administered into or in the vicinity of a patient's joint to be treated for osteoarthritis. | 2016-02-04 |
| 20160030487 | METHODS FOR SELECTION OF AGE-APPROPRIATE TISSUES - Methods of producing tissue matrices are provided. The methods can comprise selection of collagen-based tissues from animals based on desired mechanical and/or biologic properties relating to the age of a source animal. Furthermore, tissue matrices produced from animals including pigs selected at various ages to control mechanical properties are provided. | 2016-02-04 |
| 20160030488 | USE OF PLACENTAL STEM CELLS IN TREATMENT OF ACUTE KIDNEY INJURY - Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI). | 2016-02-04 |
| 20160030489 | METHODS AND APPARATUSES FOR AMNIOTIC FLUID COLLECTION AND ISOLATION OF CELLS - Disclosed herein are methods and apparatuses for the safe, high-yield collection of sterile amniotic fluid. The apparatus are configured to allow sufficient flexibility for the device to gain access to all areas of the amniotic cavity, to allow sufficient stiffness for the amniotic fluid collection device to puncture the amniotic and chorionic membranes, yet allow sufficient suppleness to pose no significant risk of maternal or fetal harm. Further disclosed are cells isolated from the full-term amniotic fluid, and methods for using, reprogramming, and differentiating these cells. | 2016-02-04 |
| 20160030490 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS - Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells. | 2016-02-04 |
| 20160030491 | PHARMACEUTICAL COMPOSITION FOR TREATING AIDS AND PREPARATION METHOD THEREOF - The present invention belongs to a pharmaceutical composition preparation field of traditional Chinese medicine, and more particularly relates to a pharmaceutical composition for treating AIDS and preparation method thereof. The pharmaceutical composition of the present invention for treating AIDS comprises the following raw medicinal materials: | 2016-02-04 |
| 20160030492 | Tumour Cytotoxic Agent and Methods Thereof - The present invention discloses a novel antitumour agent which provides an antitumour activity based on metabolites with reduced side effects. Moreover, the antitumour agent is prepared starting with a highly safe bacterium used in food production, which is a probiotic lactic acid bacterium. | 2016-02-04 |
| 20160030493 | Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria - A composition is provided comprising extracts of at least grape seeds (GSE) and green tea. The extracts are preferably polyphenolic and preferably comprises probiotic bacteria. The use of extracts from green tea and grape seeds for the manufacture of a medicament against a neurodegenerative disease is also disclosed. | 2016-02-04 |
| 20160030494 | Network-Based Microbial Compositions and Methods - Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof. | 2016-02-04 |
| 20160030495 | METHODS AND COMPOSITIONS FOR BACTERIOPHAGE THERAPY - Embodiments are directed to methods and composition for preparing and using therapeutic phage. | 2016-02-04 |
| 20160030496 | THERAPEUTIC VIRAL MICROPARTICLES FOR PROMOTING STENT BIOFUNCTIONALITY AND WOUND HEALING IN VERTEBRATE INDIVIDUALS - The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound. | 2016-02-04 |
| 20160030497 | ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS - Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed. | 2016-02-04 |
| 20160030498 | HERBAL COMPOSITIONS FOR TREATING PAIN AND SKIN DISORDERS - The invention relates to herbal compositions having standalone preparations of two phytochemicals, Bakuchiol and Boswellic acid as well as synergistic combinations of Bakuchiol with either | 2016-02-04 |
| 20160030499 | Adaptogenic Compositions And Method For Production Thereof - A composition comprising a standardized amount of a schisandrin compound and methods for production thereof for use in reducing stress, increasing blood antioxidant level, reducing lipid peroxidation and/or improving symptoms of depression in subjects in need thereof. | 2016-02-04 |
| 20160030500 | FLAVONOID-BASED COMPOSITION FOR PHARMACEUTICAL, NUTRITIONAL OR COSMETIC USE HAVING POTENTIATED ANTIOXIDANT ACTION - The invention relates to a composition for pharmaceutical or nutritional or cosmetic use, formulated for oral or topical use and possessing antioxidant activity against free radicals, comprising: a) a | 2016-02-04 |
| 20160030501 | METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY - This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31). | 2016-02-04 |
| 20160030502 | Eye Health Supplement - An eye health supplement administered to a person in order to prevent and treat eye-related conditions or diseases. The eye health supplement focuses on treating conditions and diseases, such as diabetic retinopathy, macular degeneration, hypertensive retinopathy, keratoconjunctivitis sicca, and more, and the underlying symptoms of eye-related conditions and diseases through the inclusion of a quantity of birch leaf powder, a quantity of pomegranate, a quantity of garlic bulb powder, a quantity of fenugreek powder, a quantity of curcumin, a quantity of asthaxanthin, a quantity of bilberry extract powder, and a quantity of glutathione powder. The quantity of birch leaf powder, the quantity of pomegranate, the quantity of garlic bulb powder, the quantity of fenugreek powder, the quantity of curcumin, the quantity of asthaxanthin, the quantity of bilberry extract powder, and the quantity of glutathione powder are heterogeneously mixed into a supplement mixture for oral or transdermal administration. | 2016-02-04 |
| 20160030503 | SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF - The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging. | 2016-02-04 |
| 20160030504 | METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP) - Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery. | 2016-02-04 |
| 20160030505 | COMPOSITIONS FOR PREVENTION OF ADHESIONS AND OTHER BARRIER APPLICATIONS - A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue. | 2016-02-04 |
| 20160030506 | COMBINATION COMPRISING ZIDOVUDINE AND POLYMYXIN - The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections. | 2016-02-04 |
| 20160030507 | RESISTANCE BIOMARKERS FOR HDAC INHIBITORS - Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample; quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy; and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy. Also provided is a method for identifying a cancer patient with an increased likelihood of a positive clinical response to an HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient; detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in said sample; quantifying a level of said TSPYL5 expression in said sample, wherein a low level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, identifies said cancer patient with an increased likelihood of a positive clinical response to said HDAC inhibitor therapy. Related methods and compositions are also provided. | 2016-02-04 |
| 20160030508 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE - Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof. | 2016-02-04 |
| 20160030509 | METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN - The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods. | 2016-02-04 |
| 20160030510 | METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES WITH INHIBITORS OF MICROTUBULE AFFINITY REGULATING KINASE - Methods of treating Alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (MARK). Hyperphosphorylation of tau by MARK is associated with the pathogenic deposition of intracellular neurofibrillary tangles and loss of synaptic markers, dendritic spines, and synapses during progression of Alzheimer's disease and other tauopathies. Peptide inhibitors derived from the | 2016-02-04 |
| 20160030511 | NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY - The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. | 2016-02-04 |
| 20160030512 | COMBINATION PREPARATION COMPRISING A CYTOKINE ANTAGONIST AND CORTICOSTEROID - The present invention relates to the treatment of patients with pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated. | 2016-02-04 |
| 20160030513 | Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver - The present invention provides a method of treating a subject suffering from a fatty liver disease which comprises administering to the subject a Notch decoy protein or Jagged inhibitor in an amount effective to treat the subject's fatty liver disease. | 2016-02-04 |
| 20160030514 | METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS - The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided. | 2016-02-04 |
| 20160030515 | Use of Antisecretory Factors (AF) for Optimizing Cellular Uptake - The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition. | 2016-02-04 |
| 20160030516 | PREVENTION, THERAPY AND PROGNOSIS/MONITORING IN SEPSIS AND SEPTIC SHOCK - The invention relates to the use of a peptide which binds to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), for manufacturing a pharmaceutical composition for treating sepsis or septic shock, wherein the peptide comprises the amino acid sequence of apolipoprotein CI (apoCI) or a part thereof that comprises at least the amino acids of the C-terminal helix of apoCI. The use of human apoCI is preferred. The peptide can be administered clinically to patients who have sepsis or threaten to develop sepsis. Measurement of the apoCI content in blood can be utilized for determining the severity and prognosis of the course of the septic condition or for monitoring an anti-sepsis treatment. | 2016-02-04 |
| 20160030517 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE - Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1. | 2016-02-04 |
| 20160030518 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY - The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide. | 2016-02-04 |
| 20160030519 | USE OF PACAP FOR THE TREATMENT OF VIRAL INFECTIONS IN AQUATIC ORGANISMS - The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR. | 2016-02-04 |
| 20160030520 | LIQUID INSULIN COMPOSITIONS AND METHODS OF MAKING THE SAME - Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharamaceutical Ingredient (API) preparations are substantially free of by-products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed | 2016-02-04 |
| 20160030521 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 2016-02-04 |
| 20160030522 | COMBINATION THERAPY TO IMPROVE SOFT TISSUE HEALING, FAT GRAFT HEALING, ENDOCHONDRAL BONE HEALING AND OSTEOINTEGRATION - The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM)-derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to the site of an injury such as injuries associated with osteointegration of implants and associated soft tissues, fat grafting and endochondral bone injuries and disease. | 2016-02-04 |
| 20160030523 | NOSE BLEED TREATMENT SYSTEM - A nose bleed treatment system for use in treating a patient having a nose bleed uses a nose clip that resiliently clamps the patient's nostrils to provide pressure to help stop the bleeding. A medically effective agent is sprayed in the patient's nostril using a spray bottle that has an elongated tip to apply the agent close to the source of the bleed. The medically effective agent contains at least one of a clot enhancing agent and a vasoconstricting agent. The agent may contain vitamin K as well as a vasoconstricting agent epinephrine with pytonadione (vitamin K1), menaquinone (vitamin K2), menadion (vitamin K3) fibrogen or other suitable medications. The medically effective agents are preferably herbally or mammalian sourced. | 2016-02-04 |
| 20160030524 | RECOMBINANT FACTOR VIII FORMULATIONS - Provided are liquid and lyophilized recombinant Factor VIII formulations, including formulations for polymer-conjugated FVIII such as PEGylated Factor VIII. | 2016-02-04 |
| 20160030525 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS - A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm | 2016-02-04 |
| 20160030526 | Bivalent IL-2 Fusion Toxins - IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof. | 2016-02-04 |
| 20160030527 | Compositions and Methods for Treatment of Stroke - The present invention provides compositions and methods for treating stroke. The invention relates to inhibiting the level and/or activity of cell debris after the onset of stroke. In certain embodiments, the invention provides for the catabolism or inhibition of at least one of extracellular RNA, extracellular DNA, and extracellular ATP. | 2016-02-04 |
| 20160030528 | ANTIMICROBIAL MURAMIDASE - glycosyl hydrolase 25 (GH25) muramidase is shown here to exhibit antibacterial activity against several distinct bacterial families. Formulations and methods of use for this GH25 are provided. | 2016-02-04 |
| 20160030529 | TARGETED ELIMINATION OF FACTOR VIII IMMUNE CELLS - This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor VIII antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor VIII or functional variant thereof either through a linking group or as a fusion protein. | 2016-02-04 |
| 20160030530 | SULFORAPHANE/SULFORAPHANE PRECURSOR AND PHYTOSTEROL/PHYTOSTANOL COMPOSITIONS - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a phytosterol and/or phytostanol or ester thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and a phytosterol and/or phytostanol or ester thereof. The invention also relates to the combination of a broccoli extract or powder and a phytosterol and/or phytostanol or ester thereof. The invention provides compositions and methods relating to these combinations. | 2016-02-04 |
| 20160030531 | BACTERIAL TOXINS AND USES THEREOF AS RAS SPECIFIC PROTEASES - Disclosed are bacterial toxins and uses thereof as specific proteases for Ras sarcoma oncoproteins (Ras proteins). The bacterial toxins may be modified for use as pharmaceutical agents for treating Ras-dependent diseases and disorders including cell proliferation diseases and disorders such as cancer. | 2016-02-04 |
| 20160030532 | ERYTHROCYTES CONTAINING ARGININE DEIMINASE - Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. The use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock. | 2016-02-04 |
| 20160030533 | COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS - The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of SEQ ID NOs: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of SEQ ID NOs: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 17. Additional polypeptides includes those of formula (I) [ZNZPVSSBSFSYT] | 2016-02-04 |
| 20160030534 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL AND BACTERIAL PATHOGENS - The invention features fragments of the | 2016-02-04 |
| 20160030535 | Method of Induction and Purification of a Cell Population Responsible for Vascular Mimicry and Use of Same - The disclosure provides cancer stem cells responsible for vascular mimicry, for use in stimulating immune response against a cancer. Methods for preparing and purifying the cancer stem cells are provided. | 2016-02-04 |
| 20160030536 | Cancer Vaccines And Methods Of Treatment Using The Same - Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth. | 2016-02-04 |
| 20160030537 | Individualized High Purity Glioblastoma Multiforme Stem Cells and Methods for Stimulating Immune Response - The present disclosure provides reagents and methods for stimulating an immune response against an antigen associated with glioblastoma multiforme. | 2016-02-04 |
| 20160030538 | AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS - Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject. | 2016-02-04 |
| 20160030540 | IMMUNITY INDUCING AGENT - Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 8, 10 and 12; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). | 2016-02-04 |
| 20160030541 | METHOD OF MODIFYING THE IMMUNE RESPONSE - Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs. | 2016-02-04 |
| 20160030542 | Toxoid, Compositions and Related Methods - Methods of producing purified clostridial toxin comprising tangential flow filtration, hydrophobic interaction chromatography and anion exchange chromatography are disclosed. These methods provide good yields of | 2016-02-04 |
| 20160030543 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF - In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from | 2016-02-04 |
| 20160030544 | IMMUNOGENIC COMPOSITION TO NEISSERIA - The present invention provides an immunogenic composition capable of eliciting an immune response when administered to a human or non-human animal, wherein the composition comprises an isolated protein with one or more of the following properties: i) about 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or more percent sequence identity to the protein of SEQ ID No: 1 or a fragment, derivative or analog thereof; ii) is a modified factor H binding protein, wherein the factor H binding protein has been modified at least at the position equivalent to position 318 as defined in FIG. | 2016-02-04 |
| 20160030545 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2016-02-04 |
| 20160030546 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 2016-02-04 |
